Hidradenitis suppurativa: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GIP 1
• GLP-1 1
• JAK 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT06685835· Insmed Incorporated· Updated 29 Jun 2026

  “Lack of Efficacy”Registry text, quoted unchanged. Source

• Terminated

  Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin

  NCT05066113· Johns Hopkins University· Updated 9 Jun 2026

  “Funding were insufficient to complete”Registry text, quoted unchanged. Source

• Terminated

  Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

  NCT05997277· Beth Israel Deaconess Medical Center· Updated 29 May 2026

  “Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding”Registry text, quoted unchanged. Source

• Terminated

  Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

  NCT04414514· Milton S. Hershey Medical Center· Updated 28 Apr 2026

  “The PI left the Institution and sponsor decided to close the trial.”Registry text, quoted unchanged. Source

• Terminated

  Hidradenitis - an Analysis of Genetic Traits and Linkages in Families

  NCT05710393· University of Chicago· Updated 4 Mar 2026

  “PI has left the university”Registry text, quoted unchanged. Source

• Terminated

  Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06118099· Sanofi· Updated 4 Feb 2026

  “Sponsor decision; the decision is not related to any safety concern”Registry text, quoted unchanged. Source

• Terminated

  Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

  NCT06555328· InflaRx GmbH· Updated 3 Feb 2026

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

  NCT05470322· Montefiore Medical Center· Updated 17 Dec 2025

  “No patients were able to consented/enrolled into the study during the period of time the study was approved by the IRB. Study officially withdrawn with the IRB on 11/24/2025.”Registry text, quoted unchanged. Source

• Withdrawn

  Botulinum Toxin-A for Hidradenitis Suppurativa

  NCT06237465· Yale University· Updated 16 Dec 2025

  “Study never officially began (or enrolled)”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06028230· Sanofi· Updated 11 Dec 2025

  “Sponsor decision. Not related to safety concern.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

  NCT06959225· Incyte Corporation· Source

• A Study of SL-325 in Participants With Hidradenitis Suppurativa

  NCT07934017· Shattuck Labs, Inc.· Source

• Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity

  NCT07830329· Regeneron Pharmaceuticals· Source

• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

  NCT07228390· Pfizer· Source

• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

  NCT06958211· Incyte Corporation· Source

• A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT07812116· Sanofi· Source

• An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Novartis Pharmaceuticals· Source

• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT05620836· Incyte Corporation· Source

• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

  2025-520564-17-00· MoonLake Immunotherapeutics AG· Source

• A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

  NCT07244263· Takeda· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.